|Systematic (IUPAC) name|
|Legal status||℞ Prescription only|
|Mol. mass||427.53 g/mol|
|(what is this?)|
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
- H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- Prous Science: Molecule of the Month November 2006
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|